Skip to main content

AM0010-301 AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Contain

NCT02923921

AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (ARTIST 1)

Associated Conditions

Pancreatic Cancer

Principal Investigator

Sponsor

ARMO Biosciences

The purpose of this study, which involves research, is to determine if an investigational drug, AM0010, in combination with an approved chemotherapy regimen, FOLFOX (oxaliplatin plus 5-fluorouracil (5-FU) plus leucovorin), is safe and effective when used in people with metastatic pancreatic cancer that has progressed during or following a first-line Gemcitabine containing regimen, compared with FOLFOX alone.